$KARD News
Last published 22h ago
- 22h agoKARDKardigan, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 22h agoKARDKardigan Reports Third Quarter 2026 Financial Results and Recent Business UpdatesBusiness WireSOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan today reported financial results for the third quarter ended September 30, 2026, and provided recent business updates.
- 1d agoKARDKardigan to Participate in the Jefferies Global Healthcare ConferenceBusiness WireSOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan today announced that the company will participate in a fireside chat at the 2026 Jefferies London Healthcare Conference on November 18.
- 6d agoKARDKardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic StenosisBusiness WireSOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced enrollment completion in the Phase 2b KATALYST-AV trial of ataciguat in people with aortic stenosis (AS).
- 1mo agoKARDKardigan Announces Appointment of Kristin Reinke to its Board of DirectorsBusiness WireKardigan™, Inc. (NASDAQ:KARD) ("Kardigan"), a precision cardiovascular company, announced today the appointment of Kristin Reinke to its Board of Directors, where she will serve as chair of the Audit Committee.
- 2mo agoKARDKardigan to Present at Two September Investor ConferencesBusiness WireKardigan™, Inc. (NASDAQ:KARD) ("Kardigan" or "the Company"), a clinical-stage precision therapeutics company developing medicines that target the root causes of cardiovascular diseases with no approved
- 3mo agoKARDKardigan Reports Second Quarter 2026 Financial Results and Recent Business UpdatesBusiness WireContinued to advance the development of three late-stage programs, supported by the Prolaio platform, aimed at addressing cardiovascular diseases where no approved treatments exist Danicamtiv KINSHIP-DCM Phase 3
- 4mo agoKARDKardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesBusiness WireKardigan™, Inc. (NASDAQ:KARD) ("Kardigan"), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments
- 4mo agoKARDKardigan Announces Pricing of Upsized Initial Public OfferingBusiness WireKardigan™, Inc. (NASDAQ:KARD) ("Kardigan"), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist,